Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Period	PE Ratio
2015-12-31	-53.26
2016-12-31	-39.59
2017-12-31	-34.26
2018-12-31	-35.94
2019-12-31	-38.05
2020-12-31	-72.33
2021-12-31	-33.10
2022-12-31	-28.44
2023-12-31	-21.46
2024-12-31	-19.47

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$58.59	+0.00%	0.76M
3
4
5

Xenon Pharmaceuticals Inc. (XENE) PE Ratio

PE Ratio Data

Get Xenon Pharmaceuticals Inc. Data in Excel

More XENE Financial Data